Funding
The GMMG initiated and designed the GMMG-MM5 trial and the retrospective MS study. Celgene, Janssen-Cilag, Chugai, and The Binding Site funded the trial and investigational medicinal products (bortezomib, lenalidomide). The Binding Site performed and funded the MS testing. The Dietmar Hopp Foundation in part funded infrastructure and scientists working on this project. The data presented in this manuscript were analyzed by the GMMG. Interpretation, discussion of the data, and manuscript writing/revision were done by the GMMG. Celgene, Janssen-Cilag, Chugai, and The Binding Site reviewed the manuscript. The corresponding author had unrestricted access to all trial data and had final responsibility for the decision to submit for publication. Open Access funding enabled and organized by Projekt DEAL.